Diet and Exercise for Peripheral Artery Disease
Trial Summary
What is the purpose of this trial?
This trial tests if a healthy diet combined with home walking exercises can help people with poor leg blood flow walk better and feel better overall. The diet aims to make blood vessels healthier, while the exercise improves blood flow and leg strength.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you started taking cilostazol or pentoxifylline for intermittent claudication within the last three months.
What data supports the effectiveness of the treatment DASH Diet plus Home-Based Exercise for Peripheral Artery Disease?
Research shows that combining the DASH Diet with resistance training can improve body composition and strength in older adults, which may help with physical function. Additionally, home-based exercise programs have been effective in cardiac rehabilitation, suggesting they can be a convenient and beneficial option for improving health outcomes.12345
Is home-based exercise safe for people with peripheral artery disease?
Home-based exercise programs for people with peripheral artery disease appear to be safe, with a very low rate of related adverse events. In a review of studies involving 1642 participants, only four adverse events were reported over 147,810 patient-hours of exercise, suggesting that these programs are generally well-tolerated.678910
How is the DASH Diet plus Home-Based Exercise treatment for peripheral artery disease different from other treatments?
The DASH Diet plus Home-Based Exercise treatment is unique because it combines dietary changes with a home-based exercise program, which is not commonly emphasized in traditional treatments for peripheral artery disease. This approach focuses on improving walking ability and overall health without requiring frequent visits to medical centers, making it more accessible and convenient for patients.7891112
Research Team
Andrew Gardner, Ph.D.
Principal Investigator
Professor, Department of Medicine, Cardiology
Eligibility Criteria
This trial is for individuals with Peripheral Artery Disease (PAD), specifically those who have leg pain during walking, and have either abnormal ankle-brachial index (ABI) readings or a history of procedures to improve blood flow. It's not for people without PAD, those with severe PAD symptoms like rest pain or tissue loss, recent revascularization, active cancer, certain chronic conditions, cognitive dysfunction, or on recent claudication medication.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants follow a combined DASH dietary program and home-based exercise program, or a home-based exercise program alone, for 3 months
Follow-up
Participants are monitored for changes in exercise and vascular outcomes after the intervention
Treatment Details
Interventions
- DASH Diet plus Home-Based Exercise (Behavioral Intervention)
- Home-Based Exercise (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor
Dr. Scott Rollins
University of Oklahoma
Chief Executive Officer since 2016
PhD in Immunology from the University of Oklahoma
Dr. Ondria Gleason
University of Oklahoma
Chief Medical Officer
MD from the University of Oklahoma College of Medicine
Milton S. Hershey Medical Center
Collaborator
Dr. Robert Harbaugh
Milton S. Hershey Medical Center
Chief Medical Officer since 2024
MD from Penn State College of Medicine
Don McKenna
Milton S. Hershey Medical Center
Chief Executive Officer since 2024
Master’s in Public Administration and Bachelor of Science in Business Administration and Marketing from Long Island University
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School
Case Western Reserve University
Collaborator
Eric W. Kaler
Case Western Reserve University
Chief Executive Officer since 2021
PhD in Chemical Engineering from the University of Minnesota
Stanton L. Gerson
Case Western Reserve University
Chief Medical Officer since 2020
MD from Harvard Medical School